SummaryEli Lilly’s weight-loss and diabetes drug Mounjaro became India’s top-selling medicine by value in October, surpassing GSK’s Augmentin, according to data from Pharmarack. The injectable, launched in March 2025, brought in ₹1 billion in sales as demand for GLP-1 drugs soars.